Peptide Research Guides: BPC-157, TB-500, GHK-Cu & More

Solid-phase peptide synthesis SPPS diagram showing Fmoc deprotection coupling and cleavage cycle

Solid-Phase Peptide Synthesis (SPPS): The Fmoc Method Explained

A detailed scientific explanation of Fmoc-based solid-phase peptide synthesis (SPPS) — the method used to manufacture virtually all modern research and therapeutic peptides. Covers the historical development from Merrifield's original Boc chemistry to the modern Fmoc/tBu strategy, the chemistry of each step in the synthesis cycle (resin loading, Fmoc deprotection via piperidine-mediated beta-elimination, amino acid activation and coupling, washing), the role of resins and linkers (Wang, Rink amide, 2-chlorotrityl), coupling reagent chemistry (HATU, DIC/OxymaPure, carbodiimides), common side reactions (aspartimide formation, racemization, deletion sequences, aggregation), monitoring methods (Kaiser test, UV absorbance), TFA cleavage cocktails and scavenger selection, automation and microwave-assisted synthesis, the recent wash-free SPPS breakthrough reducing solvent waste by 95%, and practical considerations for difficult sequences.

Mar 10, 2026 · 18 min read

SPPS Fmoc Solid Phase

Peptide synthesis and manufacturing guide covering SPPS Fmoc chemistry purification and lyophilization

Peptide Synthesis and Manufacturing: How Research Peptides Are Made

A comprehensive guide to how synthetic peptides are manufactured — from amino acid building blocks to purified, lyophilized research-grade products. Covers the fundamentals of solid-phase peptide synthesis (SPPS) including the Fmoc/tBu protecting group strategy, the iterative deprotection-coupling-washing cycle, resin chemistry and linker selection, coupling reagents (HATU, HBTU, DIC/OxymaPure), side-chain protection and orthogonality, TFA cleavage and global deprotection, crude peptide purification by preparative HPLC, quality control through analytical HPLC and mass spectrometry, lyophilization, disulfide bond formation, scale-up from research to GMP manufacturing, and the specific synthesis considerations for peptides like GLP-1 agonist peptide (lipidation), GLP dual agonist peptide (dual modifications), BPC-157, and AOD-9604 (disulfide cyclization).

Mar 10, 2026 · 20 min read

Peptide Synthesis SPPS Fmoc

AOD-9604 FDA GRAS regulatory history covering safety data clinical trials and legal classification

AOD-9604 FDA GRAS History and Regulatory Status

A factual analysis of AOD-9604's regulatory history, including its FDA GRAS (Generally Recognized As Safe) designation as a food ingredient, the distinction between GRAS status and drug approval, the clinical trial program that generated the safety data supporting the GRAS determination, the NOAEL findings from toxicology studies, the circumstances of pharmaceutical development termination in 2007, WADA prohibition status for competitive athletes, the current legal classification as a research chemical, and common misconceptions about what FDA GRAS means in practical and regulatory terms.

Mar 10, 2026 · 15 min read

AOD-9604 FDA GRAS

AOD-9604 stability and storage guide covering lyophilized handling reconstitution and degradation prevention

AOD-9604 Stability and Storage: Research Handling Guide

A practical scientific guide to the stability characteristics, storage requirements, and handling protocols for AOD-9604 in research settings. Covers the structural features that influence stability (disulfide bond, N-terminal tyrosine modification), degradation pathways including oxidation, hydrolysis, and aggregation, lyophilized storage conditions (-20°C long-term), reconstitution best practices with bacteriostatic water, reconstituted solution stability (2-8°C, approximately 28 days), visual indicators of degradation, the role of the disulfide bond in maintaining biological activity, and comparison with the stability profile of the unmodified hGH Fragment 176-191.

Mar 10, 2026 · 15 min read

AOD-9604 Stability Storage

AOD-9604 vs hGH Fragment 176-191 structural comparison showing tyrosine modification and differences

AOD-9604 vs hGH Fragment 176-191: Key Differences for Researchers

A scientific comparison of AOD-9604 and hGH Fragment 176-191 — two closely related but distinct peptides derived from the C-terminal region of human growth hormone. Covers the single amino acid difference (N-terminal tyrosine substitution for phenylalanine), how this modification affects stability, lipolytic potency, and research characterization, the shared core sequence and disulfide bond structure, why AOD-9604 was the compound advanced through clinical trials while the unmodified fragment was not, practical implications for research peptide selection, and how to verify identity through analytical methods.

Mar 10, 2026 · 12 min read

AOD-9604 hGH Fragment 176-191 Growth Hormone

AOD-9604 mechanism of action showing beta-3 adrenergic receptor lipolysis pathway in adipocytes

AOD-9604 Mechanism of Action: How the hGH Fragment Works

A detailed scientific analysis of how AOD-9604 exerts its metabolic effects at the molecular level. Covers the beta-3 adrenergic receptor upregulation pathway confirmed by knockout mouse studies, the cAMP-HSL-ATGL lipolytic cascade in adipocytes, simultaneous lipogenesis inhibition, the critical independence from GH receptor and JAK2-STAT5 signaling, absence of IGF-1 stimulation and diabetogenic effects, preferential action on obese versus lean adipocytes, emerging chondroprotective mechanisms in cartilage tissue, and comparison with the lipolytic mechanisms of full-length human growth hormone, GLP-1 receptor agonists, and ERR exercise mimetics.

Mar 10, 2026 · 16 min read

AOD-9604 Mechanism of Action Beta-3 Adrenergic

AOD-9604 research guide covering hGH fragment mechanism clinical trials and FDA GRAS status

AOD-9604: Complete Research Guide for Scientists

A comprehensive scientific guide to AOD-9604, the modified C-terminal fragment (amino acids 176-191) of human growth hormone with an N-terminal tyrosine substitution. Covers the discovery at Monash University by Professor Frank Ng, the beta-3 adrenergic receptor mechanism of lipolysis and lipogenesis inhibition, the critical distinction from full hGH (no IGF-1 stimulation, no diabetogenic effects, no GH receptor binding), the complete clinical trial history from Metabolic Pharmaceuticals (six human trials, 900+ subjects), the Phase IIb OPTIONS trial outcome, FDA GRAS status as a food ingredient, emerging cartilage repair and chondroprotective research, WADA prohibition status, practical handling and storage guidance, and context within the metabolic research peptide landscape.

Mar 10, 2026 · 21 min read

AOD-9604 hGH Fragment Growth Hormone

GLP-1 side effects science covering gastrointestinal tolerability pancreatitis thyroid and safety data

GLP-1 Side Effects: The Science Behind Safety and Tolerance

A scientific review of the adverse effect profile of GLP-1 receptor agonists. Covers the pharmacological mechanisms behind gastrointestinal side effects (nausea, vomiting, diarrhea, constipation), dose-titration strategies and tachyphylaxis, the pancreatitis question (FAERS signals vs RCT meta-analyses), gallbladder events and cholelithiasis risk from rapid weight loss, thyroid C-cell concerns (rodent data vs human evidence, FDA boxed warning context), perioperative aspiration risk and ASA guidance on gastric retention, muscle mass loss considerations, retinopathy signals, the January 2026 FDA removal of suicidal ideation warning, and how dual agonists like GLP dual agonist peptide may modulate GI tolerability through imbalanced receptor engagement.

Mar 10, 2026 · 18 min read

GLP-1 Side Effects Safety

GLP-1 beyond weight loss covering cardiovascular renal liver and brain research applications

GLP-1 Beyond Weight Loss: Heart, Kidney, Liver, and Brain Research

An evidence-based review of GLP-1 receptor agonist research beyond diabetes and obesity. Covers cardiovascular protection (SELECT 20% MACE reduction, LEADER, SUSTAIN-6), heart failure with preserved ejection fraction (SUMMIT trial, GLP dual agonist peptide 38% risk reduction), renal protection (FLOW trial, 24% kidney composite risk reduction, FDA CKD approval), metabolic liver disease (MASH FDA approval for GLP-1 agonist peptide, 63% resolution at 72 weeks), neurodegeneration (Alzheimer's and Parkinson's preclinical data, 48% dementia risk reduction in cohort studies, exenatide-PD3 Phase 3 outcome), addiction and substance use disorders, and the emerging multi-organ therapeutic paradigm.

Mar 10, 2026 · 20 min read

GLP-1 Cardiovascular Kidney

Oral vs injectable GLP-1 agonists formulation science comparing SNAC semaglutide and orforglipron

Oral vs Injectable GLP-1 Agonists: Formulation Science and Clinical Data

A scientific comparison of oral and injectable GLP-1 receptor agonist formulations. Covers the fundamental barriers to oral peptide delivery, SNAC absorption enhancer technology behind oral GLP-1 agonist peptide (Rybelsus), the bioavailability gap (0.8% oral vs near-complete subcutaneous absorption), dosing restrictions and their pharmacological rationale, high-dose oral GLP-1 agonist peptide (25-50 mg OASIS program), the paradigm shift to non-peptide small-molecule oral GLP-1 agonists (orforglipron Phase 3 ATTAIN data showing 12.4% weight loss at 36 mg), the ATTAIN-Maintain weight maintenance trial, and implications for peptide research and drug delivery.

Mar 10, 2026 · 19 min read

GLP-1 Oral GLP-1 agonist Orforglipron

GLP-1 receptor agonists science guide covering mechanism semaglutide tirzepatide and multi-agonists

GLP-1 Receptor Agonists: How They Work and Why They Matter

A comprehensive scientific guide to GLP-1 receptor agonists — the drug class that has transformed the treatment of type 2 diabetes and obesity. Covers the incretin effect and GLP-1 biology, receptor signaling through cAMP-PKA and PI3K-Akt pathways, central and peripheral mechanisms of appetite suppression and weight loss, the evolution from exenatide to GLP-1 agonist peptide to GLP dual agonist peptide, dual and triple agonist pharmacology, cardiovascular and renal protective effects, emerging applications in neurodegeneration and addiction, the GI tolerability profile, and the pipeline of next-generation multi-agonists including oral formulations.

Mar 10, 2026 · 22 min read

GLP-1 Receptor Agonist GLP-1 agonist

Signs a peptide has degraded showing visual analytical and functional indicators for researchers

Signs a Peptide Has Degraded: Visual, Analytical, and Functional Indicators

A practical guide for researchers to identify peptide degradation through visual inspection, analytical testing, and functional assessment. Covers observable indicators in lyophilized and reconstituted forms, HPLC and mass spectrometry signatures of common degradation products, unexpected experimental results that may indicate compromised peptide integrity, and decision frameworks for when to discard stored material versus when to continue using it.

Mar 9, 2026 · 10 min read

Peptide Degradation Quality Assessment HPLC

Research Articles